|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lung Diseases | |||||
| Lung Diseases, Obstructive | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Pulmonary Disease, Chronic Obstructive | |||||
| 3 | More general conditions related to this trial | ||||
| Respiratory Tract Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| smoking cessation | |||||
| ipratropium | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Asthmatic Agents | |||||
| Autonomic Agents | |||||
| Bronchodilator Agents | |||||
| Cholinergic Agents | |||||
| Cholinergic Antagonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Respiratory System Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||